Archives: Agenda

• Results of a collaborative industry survey on the use of AI and machine learning within clinical research and development
• Mapping AI usage and level of adoption
• Examine perceptions and attitudes regarding use of AI and machine learning and challenges to implementation

• What forced me to think strategically about clinical research training methodology
• Gaps & Risks of ‘check-the-box’ training
• Initial impact of Simulation-Based training on risk mitigation, Site time, Satisfaction, Enrollment and Quality
• Advances in Simulation-Based training that enhance site and patient engagement as well as optimize protocols

• Understanding the role of Key Opinion Leaders beyond data collection
• Educating CRAs on the impact of safeguarding future customer relationships
• Prioritizing site satisfaction for patient happiness
• Enhancing patient outcomes through site relationship building

• Identifying outsourcing opportunities and pitfalls to avoid that can be addressed through AI driven solutions: timeline standards, document prep and system utilization
• Developing operationally, process and system driven AI models to support clinical operations and outsourcing: what can be streamlined?
• Integrating AI insights into outsourcing strategy to drive speed, quality and cost effectiveness: timelines, project management and reconciliation

• Importance of retention and growth for your team
• Openness to junior clinical team members
• Openness to bridge programs with vendor partner
• Navigating these challenges in a hybrid environment

• Priorities and strategies for small biotech in partnering with CROs and vendors
• Breaking down the myths
• Identifying the right partners
• Cultivating collaborative relationships
• Managing the partnership

• Overview of the value proposition and expected financial return of patient engagement practices
• Review of current adoption levels of patient engagement practices
• Assessment of the impact of patient engagement practices on performance and quality
• Discussion of opportunities to optimize patient engagement and its impact

• Developing relationships with advocacy groups and patient communities from early stages
• How does patient advocacy differ at biotechs vs large pharma?
• Integrating patient insights into your study to ensure patients remain the priority throughout your trial

MODERATOR Hollie Schmidt, Vice President, Scientific Operations, Accelerated Cure Project for MS